EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Treatments and outcomes in high‐risk gestational trophoblastic neoplasia: A systematic review and meta‐analysis

Benjamin B Albright iD, Tressa Ellett, Hope E Knochenhauer, Emily C Goins, Karen A Monuszko, Samantha J Kaplan, Rebecca A Previs, Haley A Moss, Laura J Havrilesky, Brittany A Davidson

BJOG: An International Journal of Obstetrics & Gynaecology · 2023

DOI: 10.1111/1471-0528.17374 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2023. Verfasst von Benjamin B Albright und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Gestational Trophoblastic Disease, Hydatidiform Mole. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐risk gestational trophoblastic neoplasia (GTN) is rare and treated with diverse approaches. Limited published institutional data has yet to be systematically reviewed.

Objectives

To compile global high‐risk GTN (prognostic score ≥7) cohorts to summarise treatments and outcomes by disease characteristics and primary chemotherapy. Search Strategy MEDLINE, Embase, Scopus, ClinicalTrials.gov and Cochrane were searched through March 2021. Selection Criteria Full‐text manuscripts reporting mortality among ≥10 high‐risk GTN patients. Data Collection and Analysis Binomial proportions were summed, and random‐effects meta‐analyses performed. Main Results From 1137 records, we included 35 studies, representing 20 countries. Among 2276 unique high‐risk GTN patients, 99.7% received chemotherapy, 35.8% surgery and 4.9% radiation. Mortality was 10.9% (243/2236; meta‐analysis: 10%, 95% confidence interval [CI] 7–12%) and likelihood of complete response to primary chemotherapy was 79.7% (1506/1890; meta‐analysis: 78%, 95% CI: 74–83%). Across 24 reporting studies, modern preferred chemotherapy (EMA/CO or EMA/EP) was associated with lower mortality (overall: 8.8 versus 9.5%; comparative meta‐analysis: 8.1 versus 12.4%, OR 0.42, 95% CI: 0.20–0.90%, 14 studies) and higher likelihood of complete response (overall: 76.6 versus 72.8%; comparative meta‐analysis: 75.9 versus 60.7%, OR 2.98, 95% CI: 1.06–8.35%, 14 studies), though studies focused on non‐preferred regimens reported comparable outcomes. Mortality was increased for ultra‐high‐risk disease (30 versus 7.5% high‐risk; meta‐analysis OR 7.44, 95% CI: 4.29–12.9%) and disease following term delivery (20.8 versus 7.3% following molar pregnancy; meta‐analysis OR 2.64, 95% CI: 1.10–6.31%). Relapse rate estimates ranged from 3 to 6%.

Conclusions

High‐risk GTN is responsive to several chemotherapy regimens, with EMA/CO or EMA/EP associated with improved outcomes. Mortality is increased in patients with ultra‐high‐risk, relapsed and post‐term pregnancy disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gestational Trophoblastic DiseaseHydatidiform MolePregnancyFemaleHumansMethotrexateDactinomycinNeoplasm Recurrence, LocalRetrospective Studies

Stichwörter der Autor:innen

gestational trophoblastic diseasegestational trophoblastic disease - choriocarcinomameta-analysissystematic reviews

Substanzen

MethotrexateDactinomycin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA.
  • Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Benjamin B Albright

Förderung

  • NICHD NIH HHS

Zitieren

APA

Albright, B. B., Ellett, T., Knochenhauer, H. E., Goins, E. C., Monuszko, K. A., Kaplan, S. J., Previs, R. A., Moss, H. A., Havrilesky, L. J., & Davidson, B. A. (2023). Treatments and outcomes in high‐risk gestational trophoblastic neoplasia: A systematic review and meta‐analysis. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17374

Vancouver

Albright BB, Ellett T, Knochenhauer HE, Goins EC, Monuszko KA, Kaplan SJ, et al. Treatments and outcomes in high‐risk gestational trophoblastic neoplasia: A systematic review and meta‐analysis. BJOG: An International Journal of Obstetrics & Gynaecology. 2023. doi:10.1111/1471-0528.17374

BibTeX
@article{Albright2023,
  author = {Albright, Benjamin B and Ellett, Tressa and Knochenhauer, Hope E and Goins, Emily C and Monuszko, Karen A and Kaplan, Samantha J and Previs, Rebecca A and Moss, Haley A and Havrilesky, Laura J and Davidson, Brittany A},
  title = {Treatments and outcomes in high‐risk gestational trophoblastic neoplasia: A systematic review and meta‐analysis},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2023},
  doi = {10.1111/1471-0528.17374}
}
Kostenlos starten →